Caris Life Sciences provides cancer molecular profiling tests and related data services for doctors, researchers and drug developers. CAI reports earnings on Wed, Nov 4, 2026. Analyst consensus is Buy, based on the latest ratings from 6 firms (4 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in CAI, 33% of them bullish and 67% bearish. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | Canaccord Genuity | Maintained | Hold | |
| Oct 14 | JP Morgan | Maintained | Buy | |
| Oct 13 | TD Cowen | Maintained | Buy | |
| Sep 9 | UBS | Initiated | Hold | |
| Aug 7 | BTIG | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in CAI in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CAI is in one of them and how their past CAI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CAI in an article yet. Here's the latest on the wider market.
About Caris Life Sciences
Caris Life Sciences, based in Irving, Texas, offers molecular profiling tests that analyze tumor tissue and blood samples to help guide cancer care. Its tests combine gene sequencing with artificial intelligence analysis, and it also sells data and bioinformatics services. Its customers include physicians and clinical labs, academic cancer research centers, and biopharma companies developing new drugs. The company focuses mainly on oncology.
- Headquarters
- Irving, TX